ENDPOINTS NEWS

Biogen ends agreement with Acorda for multiple sclerosis drug Fampyra

by **Katherine Lewin on January 11th, 2024**

Biogen is handing back ex-US commercialization rights to Acorda Therapeutics for the multiple sclerosis drug Fampyra.

Acorda will have the drug in-house effective Jan. 1, 2025, now that Biogen has decided to terminate the license and collaboration agreement between the two companies. The drug is marketed as Fampyra (fampridine) in the EU as a treatment to improve the walking of adults with multiple sclerosis and a walking disability.

A Biogen spokesperson told *Endpoints News* that the company made the decision to "return commercialization rights to Acorda in order to shift resources to support upcoming launches and programs that align with the company's priorities to return to sustainable growth."

Acorda markets the drug in the US, where it is approved as Ampyra.

Acorda said in a Thursday release that it will take on commercialization and supply of Fampyra for multiple sclerosis patients outside of the US. Acorda said it plans to take over commercialization "as soon as possible" this year.

Ron Cohen

“We are excited to bring FAMPYRA in-house, which we believe will add significant value to Acorda, and allow us to continue to provide access to this important medication for people with MS around the world,” Acorda president and CEO Ron Cohen said in a statement.

Ampyra brought in a net revenue of $15.7 million in the third quarter of 2023 for Acorda, a 26% decrease over the third quarter of 2022, and Fampyra royalties of $2.5 million. In its latest financial report, Acorda said that Ampyra lost its exclusivity in 2018 and generics entered the market, and the company expects Ampyra revenue to continue its decline. For the full year 2023, Acorda expects net revenue guidance to be $65 million to $70 million for Ampyra.

Fampyra brought in $67.5 million in revenue for Biogen in the first nine months of 2023.

Read this article on the website